The German vaccine maker intends to use AI tech to speed up drug discovery and development of next-generation immunotherapies and vaccines.

InstaDeep shareholders will also be eligible to receive additional performance-based milestone payments of up to 200 million euros.

BioNTech said last year it developed a method to quickly determine whether a new virus variant is a cause for concern, collaborating with InstaDeep Ltd.

($1 = 0.9325 euros)

(Reporting by Pratik Jain; Editing by Shinjini Ganguli and Shailesh Kuber)